Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 3/2024

20-02-2024 | Prostate Cancer | REVIEW

Perspectives on the Cardiovascular and Metabolic Effects of Androgen Deprivation Therapy in Prostate Cancer

Authors: Daniel Sentana-Lledo, Alicia K. Morgans

Published in: Current Oncology Reports | Issue 3/2024

Login to get access

Abstract

Purpose of Review

Cardiovascular disease (CVD) is the leading cause of non-cancer mortality in men with prostate cancer. This review summarizes the existing and emerging literature examining the cardiometabolic effects of androgen deprivation therapy (ADT) in prostate cancer.

Recent Findings

The evidence behind the metabolic effects of ADT is derived from older studies and has not been validated in modern cohorts. Most of the newer studies focus on the risk of cardiovascular disease (CVD) with ADT. Recently published studies like the HERO and PRONOUNCE trials have once again sparked debate about the effects of different types and durations of ADT on cardiovascular outcomes.

Summary

The link between ADT and CVD is inherently complex with a majority of the evidence collected from population-based or non-randomized trials without enriching for high-risk populations. Ongoing clinical trials may provide more informative data to guide the cardiovascular care of prostate cancer survivors.
Literature
1.
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.CrossRefPubMed
2.
Resnick MJ, Lacchetti C, Bergman J, Hauke RJ, Hoffman KE, Kungel TM, et al. Prostate cancer survivorship care guideline: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol. 2015;33(9):1078–85.PubMedCrossRef
3.
Kim J, Freeman K, Ayala A, Mullen M, Sun Z, Rhee JW. Cardiovascular impact of androgen deprivation therapy: from basic biology to clinical practice. Curr Oncol Rep. 2023;25(9):965–77.PubMedPubMedCentralCrossRef
4.
Tisseverasinghe S, Tolba M, Saad F, Gravis G, Bahoric B, Niazi T. Should prostate cancer patients with history of cardiovascular events be preferentially treated with luteinizing hormone-releasing hormone antagonists? J Clin Oncol. 2022;40(36):4173–7.PubMedCrossRef
5.
Elmehrath AO, Afifi AM, Al-Husseini MJ, Saad AM, Wilson N, Shohdy KS, et al. Causes of death among patients with metastatic prostate cancer in the US from 2000 to 2016. JAMA Netw Open. 2021;4(8):e2119568.PubMedPubMedCentralCrossRef
6.
Ye Y, Zheng Y, Miao Q, Ruan H, Zhang X. Causes of death among prostate cancer patients aged 40 years and older in the United States. Front Oncol. 2022;1(12):914875.CrossRef
7.
Gupta D, Lee Chuy K, Yang JC, Bates M, Lombardo M, Steingart RM. Cardiovascular and metabolic effects of androgen-deprivation therapy for prostate cancer. J Oncol Pract. 2018;14(10):580–7.PubMedCrossRef
8.
Smith MR, Finkelstein JS, Mcgovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87(2):599–603.PubMedCrossRef
9.
Smith MR, Lee H, McGovern F, Fallon MA, Goode M, Zietman AL, et al. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer. Cancer. 2008;112(10):2188–94.PubMedCrossRef
10.
Smith MR, Saad F, Egerdie B, Sieber PR, Tammela TLJ, Ke C, et al. Sarcopenia during androgen-deprivation therapy for prostate cancer. J Clin Oncol. 2012;30(26):3271–6.PubMedPubMedCentralCrossRef
11.
Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006;91(4):1305–8.PubMedCrossRef
12.
Smith MR, Lee H, Fallon MA, Nathan DM. Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer: evidence for a distinct hypogonadal metabolic syndrome? Urology. 2008;71(2):318–22.PubMedCrossRef
13.
Alibhai SMH, Duong-Hua M, Sutradhar R, Fleshner NE, Warde P, Cheung AM, et al. Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol. 2009;27(21):3452–8.PubMedCrossRef
14.
Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448–56.PubMedCrossRef
15.
Keating NL, Liu PH, O’Malley AJ, Freedland SJ, Smith MR. Androgen deprivation therapy and diabetes control among diabetic men with prostate cancer. Eur Urol. 2014;65(4):816–24.PubMedCrossRef
16.
Bourghardt J, Wilhelmson ASK, Alexanderson C, De Gendt K, Verhoeven G, Krettek A, et al. Androgen receptor-dependent and independent atheroprotection by testosterone in male mice. Endocrinology. 2010;151(11):5428–37.PubMedCrossRef
17.
Nathan L, Shi W, Dinh H, Mukherjee TK, Wang X, Lusis AJ, et al. Testosterone inhibits early atherogenesis by conversion to estradiol: critical role of aromatase. Proc Natl Acad Sci U S A. 2001;98(6):3589–93.ADSPubMedPubMedCentralCrossRef
18.
Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab. 2001;86(9):4261–7.PubMedCrossRef
19.
Dockery F, Bulpitt CJ, Agarwal S, Vernon C, Rajkumar C. Effect of androgen suppression compared with androgen receptor blockade on arterial stiffness in men with prostate cancer. J Androl. 2009;30(4):410–5.PubMedCrossRef
20.
Narayan V, Harrison M, Cheng H, Kenfield S, Aggarwal R, Kwon D, et al. Improving research for prostate cancer survivorship: a statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. Urol Oncol Semin Orig Investig. 2020;38(3):83–93.
21••.
Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, et al. Oral relugolix for androgen-deprivation therapy in advanced prostate cancer. N Engl J Med. 2020 Jun 4;382(23):2187–96. ** Pivotal HERO trial identifying decreased MACE with relugolix compared to GnRH agonists.
22.
Leong DP, Fradet V, Shayegan B, Duceppe E, Siemens R, Niazi T, et al. Cardiovascular risk in men with prostate cancer: insights from the RADICAL PC study. J Urol. 2020;203(6):1109–16.PubMedCrossRef
23.
Bosco E, Hsueh L, McConeghy KW, Gravenstein S, Saade E. Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review. BMC Med Res Methodol. 2021;6(21):241.CrossRef
24••.
Lopes RD, Higano CS, Slovin SF, Nelson AJ, Bigelow R, Sørensen PS, et al. Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial. Circulation. 2021 Oct 19;144(16):1295–307. ** Only phase III trial with CVD as the primary outcome associated with GnRH agonists and antagonists.
25•.
Bonsu JM, Guha A, Charles L, Yildiz VO, Wei L, Baker B, et al. Reporting of cardiovascular events in clinical trials supporting FDA approval of contemporary cancer therapies. J Am Coll Cardiol. 2020 Feb 18;75(6):620–8. *Analysis identifying incorrect reporting of cardiovascular events in cancer clinical trials
26.
Van Hemelrijck M, Garmo H, Holmberg L, Ingelsson E, Bratt O, Bill-Axelson A, et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the population-based PCBaSe Sweden. J Clin Oncol. 2010;28(21):3448–56.PubMedCrossRef
27.
Jespersen CG, Nørgaard M, Borre M. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol. 2014;65(4):704–9.PubMedCrossRef
28.
O’Farrell S, Garmo H, Holmberg L, Adolfsson J, Stattin P, Van Hemelrijck M. Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer. J Clin Oncol. 2015;33(11):1243–51.PubMedCrossRef
29.
Zhao J, Zhu S, Sun L, Meng F, Zhao L, Zhao Y, et al. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies. PLoS ONE. 2014;9(9):e107516.ADSPubMedPubMedCentralCrossRef
30.
Carneiro A, Sasse AD, Wagner AA, Peixoto G, Kataguiri A, Neto AS, et al. Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis. World J Urol. 2015;33(9):1281–9.PubMedCrossRef
31.
Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, Van Hemelrijck M. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol. 2015;68(3):386–96.PubMedCrossRef
32.
Meng F, Zhu S, Zhao J, Vados L, Wang L, Zhao Y, et al. Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review. BMC Cancer. 2016;16(1):180.PubMedPubMedCentralCrossRef
33.
Kim DK, Lee HS, Park JY, Kim JW, Ha JS, Kim JH, et al. Does androgen-deprivation therapy increase the risk of ischemic cardiovascular and cerebrovascular diseases in patients with prostate cancer? A nationwide population-based cohort study. J Cancer Res Clin Oncol. 2021;147(4):1217–26.PubMedCrossRef
34.
Nguyen PL, Je Y, Schutz FAB, Hoffman KE, Hu JC, Parekh A, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA. 2011;306(21):2359–66.PubMedCrossRef
35.
Hopmans SN, Duivenvoorden WCM, Werstuck GH, Klotz L, Pinthus JH. GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model. Urol Oncol Semin Orig Investig. 2014;32(8):1126–34.
36.
Knutsson A, Hsiung S, Celik S, Rattik S, Mattisson IY, Wigren M, et al. Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE−/− mice. Sci Rep. 2016;18(6):26220.ADSCrossRef
37.
Albertsen PC, Klotz L, Tombal B, Grady J, Olesen TK, Nilsson J. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol. 2014;65(3):565–73.PubMedCrossRef
38.
Gu L, Li X, Liu W. Adverse cardiovascular effect following gonadotropin-releasing hormone antagonist versus GnRH agonist for prostate cancer treatment: a systematic review and meta-analysis. Front Endocrinol. 2023;31(14):1157857.CrossRef
39.
Davey P, Kirby MG. Cardiovascular risk profiles of GnRH agonists and antagonists: real-world analysis from UK general practice. World J Urol. 2021;39(2):307–15.PubMedCrossRef
40.
Perrone V, DegliEsposti L, Giacomini E, Veronesi C, Blini V, Oderda M. Cardiovascular risk profile in prostate cancer patients treated with GnRH agonists versus antagonists: an Italian real-world analysis. Ther Clin Risk Manag. 2020;7(16):393–401.CrossRef
41.
George G, Garmo H, Scailteux LM, Balusson F, Coster GD, Schutter HD, et al. Risk of cardiovascular disease following gonadotropin-releasing hormone agonists vs antagonists in prostate cancer: real-world evidence from five databases. Int J Cancer. 2021;148(9):2203.PubMedCrossRef
42.
Scailteux LM, Vincendeau S, Balusson F, Leclercq C, Happe A, Le Nautout B, et al. Androgen deprivation therapy and cardiovascular risk: no meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010–2013 French Health Insurance data. Eur J Cancer Oxf Engl. 2017;1990(77):99–108.CrossRef
43.
44.
Margel D, Peer A, Ber Y, Shavit-Grievink L, Tabachnik T, Sela S, et al. Cardiovascular morbidity in a randomized trial comparing GnRH agonist and GnRH antagonist among patients with advanced prostate cancer and preexisting cardiovascular disease. J Urol. 2019;202(6):1199–208.PubMedCrossRef
45.
Jin C, Fan Y, Meng Y, Shen C, Wang Y, Hu S, et al. A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients. Prostate Cancer Prostatic Dis. 2016;19(4):333–9.PubMedCrossRef
46.
Morgans AK, Ebrahimi R, Bobbili PJ, Nwokeji E, Gandhi R, Desai R, et al. Association of intermittent or continuous androgen deprivation therapy with cardiovascular disease and endocrine/metabolic disorders in patients with nonmetastatic prostate cancer. J Clin Oncol. 2023;41:83–83.CrossRef
47.
Hershman DL, Unger JM, Wright JD, Ramsey S, Till C, Tangen CM, et al. Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer. JAMA Oncol. 2016;2(4):453–61.PubMedPubMedCentralCrossRef
48.
McMaster University. The role of androgen deprivation therapy in cardiovascular disease - a longitudinal prostate cancer study (RADICAL PC1) & a RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients (RADICAL PC2) [Internet]. clinicaltrials.gov; 2023 Sep [cited 2022 Dec 31]. Report No.: NCT03127631. https://​clinicaltrials.​gov/​study/​NCT03127631
49.
Narayan V. The CArdiovascular Risk Evaluation in Men With Prostate Cancer Study (CARE-PC): initial pilot feasibility study to assess patient awareness and risk mitigation [Internet]. clinicaltrials.gov; 2023 Oct [cited 2022 Dec 31]. Report No.: NCT06064149. https://​clinicaltrials.​gov/​study/​NCT06064149
50.
M.D. Anderson Cancer Center. Modifying metabolic syndrome and cardiovascular risk for prostate cancer patients on ADT using a supervised exercise program and continuous Fitbit monitoring [Internet]. clinicaltrials.gov; 2023 Mar [cited 2022 Dec 31]. Report No.: NCT05054296. https://​clinicaltrials.​gov/​study/​NCT05054296
51.
Myovant Sciences GmbH. Relugolix versus leuprolide in patients with prostate cancer: a randomized, open-label study to assess major adverse cardiovascular events (REPLACE-CV) [Internet]. clinicaltrials.gov; 2023 Nov [cited 2022 Dec 31]. Report No.: NCT05605964. https://​clinicaltrials.​gov/​study/​NCT05605964
Metadata
Title
Perspectives on the Cardiovascular and Metabolic Effects of Androgen Deprivation Therapy in Prostate Cancer
Authors
Daniel Sentana-Lledo
Alicia K. Morgans
Publication date
20-02-2024
Publisher
Springer US
Published in
Current Oncology Reports / Issue 3/2024
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-024-01512-x

Other articles of this Issue 3/2024

Current Oncology Reports 3/2024 Go to the issue

REVIEW

Pelvic Floor Therapy and Initial Interventions for Pelvic Floor Dysfunction in Gynecologic Malignancies

REVIEW

Oral Health in Patients with History of Head and Neck Cancer: Complexity and Benefits of a Targeted Oral Healthcare Pathway

Review

Geographical Disparities in Lung Cancer in Canada: A Review

Review

The Dairy and Cancer Controversy: Milking the Evidence

REVIEW

Blood–Brain Barrier Disruption for the Treatment of Primary Brain Tumors: Advances in the Past Half-Decade

REVIEW

Establishing an Integrative Oncology Service: Essential Aspects of Program Development
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits